Pfizer – NSCLC Biomarker Testing – Request for Proposals

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire with your unit

Memorial Deadline: Friday 18th, June 2021

External Deadline: Wednesday 23rd, June 2021


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Projects that will be considered for Pfizer support will be Quality Improvement initiatives that analyze and improve biomarker testing practices in NSCLC. 

For patients diagnosed with metastatic NSCLC, sub-optimal biomarker testing practices continue to exist. A high percentage of patients are initiated on therapy before the care team receives the results of a comprehensive biomarker testing panel. For some patients, standardized biomarker tests are not performed at all. 

Grant support is available to cancer centers or hospitals interested in forming multi-disciplinary teams to analyze their own testing practices and identify areas of improvement using Quality Improvement (QI) methodology such as root cause analysis, Plan Do Study Act (PDSA) cycles etc. It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5)

Additional information can be found here.

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: April 27, 2021